☆
Watchlist
Log in
Sign-up
Amplia Therapeutics Ltd (atx) Logo

Amplia Therapeutics Ltd (ATX)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials (10-yr)

ATX Chart

Snapshot

ATX's Principal Activity is the development of Focal Adhesion Kinase (FAK) inhibiting drug candidates AMP886 and AMP945.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -46.64%
vs ASX 200 (1yr) -50.74%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,684 of 2,411
Sector Rank 156 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies SUD / ICS / IME
EPS -$0.029
DPS $0.00
Book Value Per Share $0.09

Broker Consensus

ATX is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Top Market Index News

More News

Announcements

Date Heading Pages File Size Time

Corporate Overview

Amplia Therapeutics Limited (ATX, formerly Innate Immunotherapeutics Limited) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Melbourne VIC 3000
Website www.ampliatx.com
Registry Computershare
Auditor Grant Thornton Audit Pty Ltd
Date Listed 23 Dec 2013

Upcoming Calendar (Forecasted)

Date Event
30/05/2022 Report (Prelim)
22/07/2022 Report (Annual)
23/11/2022 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.
Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Ms S Jane Catherine Bell Non-Executive Director Apr 2021

Ms S Jane Catherine Bell

Non-Executive Director

Ms Bell is a non-executive director with more than 30 years' experience in law firms, financial services and corporate treasury operations gained living in Melbourne, London, Toronto, San Francisco and Brisbane. Jane has been a non-executive director since 2002, serving on 12 boards including nine health and medical research boards. Jane currently serves as Deputy Chair of Monash Health, Director of Jessie McPherson Private Hospital, Chair of the Community Advisory Group of the Melbourne Genomics Health Alliance and is a Member of the Administrative Appeals Tribunal. Jane is a former Chair of Melbourne Health (Royal Melbourne Hospital), Chair of Biomedical Research Vic, Deputy Chair of Westernport Water Corporation, Director of UCA Funds Management, WorkSafe Victoria, Hudson Institute of Medical Research-Monash Institute of Medical Research-Prince Henry's Institute of Medical Research, Queensland Institute of Medical Research Trust, Australian Red Cross (Qld) and Victorian Women's Housing Association.
Dr John Lambert Chief Executive Officer,Managing Director Jun 2019

Dr John Lambert

Chief Executive Officer,Managing Director

Dr Lambert has more than 18 years of drug discovery and development experience. His prior appointments included leadership roles in Drug Development, Operations Management and Drug Discovery (Biota Pharmaceuticals), primarily working on the development of respiratory antiviral drugs. As a Senior Director at Medicines Development for Global Health, John was a member of the team that received approval in 2018 from the US FDA for moxidectin as a treatment for river blindness. Prior to working in industry John was an academic researcher in organic, medicinal and biological chemistry (University of Melbourne, ANU and Harvard University). John is an experienced manager of both in early and late development of therapeutics and has built and led multidisciplinary project teams tasked with the objective of delivering clinical proof-of-concept for new products. As such, his experience spans the entire spectrum of drug development from design of development strategy through project management, manufacture, formulation, pre-clinical and clinical development and regulatory affairs.

Dr Warwick Bonner Tong Non-Executive Director,Non-Executive Chairman May 2018

Dr Warwick Bonner Tong

Non-Executive Director,Non-Executive Chairman

Dr Tong is a NZ trained physician with more than 25 years experience in the Pharmaceutical and Biotechnology industry. After his early career in General Medical Practice Warwick has held a wide variety of roles in the pharmaceutical and biotech industry in NZ(Glaxo) Singapore (GlaxoWellcome) London (GSK), Boston (Surface Logix) and Melbourne (CTx - Cancer Therapeutics CRC). Warwick currently serves as director of Aculeus Therapeutics Pty Ltd, CannaPacific Pty Ltd and its affiliate e3D Pharma Pty Ltd. He is a member of the Strategic Advisory Board of the Maurice Wilkins Centre in Auckland NZ and of the CSIRO Manufacturing Business Advisory Committee. Warwick is a former CEO and director of CTx, director and Chair of the CTx commercialisation company, CTxONE, and director and Chair of BioMedVic.

Dr Christopher John Burns Non-Executive Director May 2018

Dr Christopher John Burns

Non-Executive Director

Dr Burns is an experienced drug discovery leader having worked in various roles in pharma, biotech and academia for 25 years. After completing a PhD in Organic Chemistry at the University of Melbourne Chris undertook post-doctoral studies in the USA before moving to Pfizer UK, where he worked on a variety of drug discovery projects. After 5 years he returned to Australia as a Research Fellow at the University of Sydney with the CRC for Molecular Engineering and Technology and after two years moved to the biotechnology company Ambri as Head of Chemistry. Chris then moved to the Melbourne-based biotech as Head of Medicinal Chemistry and later as Research Director. During this time he led teams in the discovery of two anti-cancer agents that have entered clinical trial, including the drug momelotinib which successfully completed Phase III studies. Most recently Chris was a Laboratory Head at the Walter and Eliza Hall Institute of Medical Research in Melbourne and currently holds executive roles with privately held biotechs MecRx, Certa Therapeutics and OccuRx. Dr Burns is the inventor on over 30 patents and a co-author on over 50 scientific publications.

Dr Robert Peach Non-Executive Director Sep 2015

Dr Robert Peach

Non-Executive Director

Dr Peach has 30 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry. In 2009 he co-founded Receptos Limited, becoming Chief Scientific Officer and raising US$59M in venture capital and US$800M in an IPO and three subsequent follow-on offerings. In August 2015 Receptos was acquired by Celgene for US$7.8B. Robert held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture investments. His drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs. He is currently on the Board of Directors of AdAlta Pty Limited and Rekover Therapeutics, and serves on the Scientific Advisory Board of Eclipse Bioinnovations. Robert is the co-author of 70 scientific publications and book chapters, and 26 patents and patent applications.

Mr Andrew John Cooke Company Secretary Oct 2013

Mr Andrew John Cooke

Company Secretary

Mr Cooke has experience in law, corporate finance, governance and compliance. As a Non-Executive Director and Company Secretary of a number of ASX listed companies he has over 25 years of boardroom experience and has developed a practical blend of legal and commercial acumen. He has served as a consultant to listed, public and private companies in the resources, property and biotech sectors focussing on stock exchange and regulatory compliance and a wide range of corporate transactions. Andrew has been the Company Secretary since 11 October 2013.
Jeff Carter Chief Financial Officer N/A
Mark Devlin Chief Science Officer N/A
Rhiannon Jones Director, Operations N/A
Show All

Director Transactions

ATX directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
10/02/22 S Jane Bell Buy +127,136 $0.17 $21,613 On-market trade
09/02/22 S Jane Bell Buy +72,864 $0.17 $12,386 On-market trade
04/02/22 S Jane Bell Buy +22,342 $0.16 $3,574 On-market trade
20/12/21 S Jane Bell Buy +714,285 $0.145 $103,571 On-market trade
15/12/21 S Jane Bell Issued 72,590 $0.17 $12,340 Rights issue
15/12/21 S Jane Bell Issued 148,479 $0.18 $26,726 Rights issue
15/12/21 S Jane Bell Issued 69,291 $0.18 $12,472 Rights issue
15/12/21 Christopher Burns Issued 18,519 $0.17 $3,148 Rights issue
15/12/21 Christopher Burns Issued 55,555 $0.18 $9,999 Rights issue
15/12/21 Robert Peach Issued 110,984 $0.17 $18,867 Rights issue
15/12/21 Robert Peach Issued 332,952 $0.18 $59,931 Rights issue
15/12/21 John Lambert Issued 29,168 $0.17 $4,958 Rights issue
15/12/21 John Lambert Issued 32,500 $0.18 $5,850 Rights issue
15/12/21 John Lambert Issued 55,000 $0.18 $9,900 Rights issue
15/12/21 Warwick Tong Issued 100,000 $0.18 $18,000 Rights issue
15/12/21 Warwick Tong Issued 33,334 $0.17 $5,666 Rights issue
02/09/21 S Jane Bell Buy +557,646 $0.207 $115,432 On-market trade
01/09/21 S Jane Bell Buy +36,268 $0.19 $6,890 On-market trade
07/06/21 John Lambert Issued 130,000 $0.155 $20,150 Exercise of options
07/06/21 John Lambert Exercise 130,000 $0.155 $20,150 Exercise of options
18/09/20 Robert Peach Issued 275,808 $0.127 $35,000 Director remuneration
18/09/20 Christopher Burns Issued 197,006 $0.127 $25,000 Director remuneration
18/09/20 Warwick Tong Issued 413,712 $0.127 $52,500 Director remuneration
04/08/20 John Lambert Issued 120,000 $0.10 $12,000 Rights issue
04/08/20 Warwick Tong Issued 150,000 $0.10 $15,000 Rights issue
13/07/20 Warwick Tong Issued 200,000 $0.10 $20,000 Rights issue
17/09/19 Robert Peach Transfer 56,000 $0.08 $4,480 Off-market transfer
17/09/19 Robert Peach Issued 500,000 $0.08 $40,000 Placement
17/09/19 Robert Peach Transfer 56,000 $0.08 $4,480 Off-market transfer
17/09/19 Christian Behrenbruch Issued 125,000 $0.08 $10,000 Placement
17/09/19 Warwick Tong Issued 125,000 $0.08 $10,000 Placement
17/09/19 Christian Behrenbruch Issued 250,000 $0.10 $25,000 Placement
17/09/19 Warwick Tong Issued 250,000 $0.10 $25,000 Placement
17/09/19 Robert Peach Issued 1,000,000 $0.10 $100,000 Placement
20/08/19 Simon Wilkinson Expiry 175,000 $0.077 $13,475 Options expired
02/08/19 Warwick Tong Issued 80,000 $0.10 $8,000 Rights issue
02/08/19 Christopher Burns Issued 30,000 $0.098 $2,940 Rights issue
02/08/19 Warwick Tong Issued 40,000 $0.098 $3,920 Rights issue
02/08/19 Andrew Cooke Issued 63 $0.098 $6 Rights issue
02/08/19 Andrew Cooke Issued 125 $10.001 $1,250 Rights issue
02/08/19 Christopher Burns Issued 60,000 $0.10 $6,000 Rights issue
Show All

Director Interests

The current holdings of ATX directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
S Jane Bell 10/02/2022 346,454 1,679,020 72,590 N/A
Christopher Burns 15/12/2021 2,527,798 N/A 48,519 N/A
Warwick Tong 15/12/2021 2,855,140 N/A 198,334 N/A
Robert Peach 15/12/2021 0 1,664,760 1,090,984 N/A
John Lambert 15/12/2021 162,500 275,000 1,899,168 N/A
Andrew Cooke 06/02/2020 375 N/A 480,063 N/A
Show All

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Jul 13, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
HSBC Custody Nominees (Australia) Limited 20,374,618 16.32%
Bond Street Custodians Limited <Lam1 D08047 A/C> 8,750,000 7.01%
Citicorp Nominees Pty Limited 5,803,803 4.65%
BNP Paribas Noms Pty Ltd <Drp> 4,595,985 3.68%
Ctxt Pty Ltd 4,514,468 3.62%
Elk River Holdings Pty Ltd 2,942,142 2.36%
Christopher John Burns 2,472,243 1.98%
Warwick Tong 2,355,140 1.89%
34Th Avenue Pty Ltd <Devlin Family A/C> 2,215,237 1.77%
Gp Securities Pty Ltd 1,930,000 1.55%
Mr Andrew Podolak 1,925,000 1.54%
Mark Sullivan <Aems Consulting A/C> 1,661,428 1.33%
Cancer Research Technology Limited 1,360,524 1.09%
HWH Power Pty Ltd <Hwh Super Fund A/C> 1,270,000 1.02%
Merrill Lynch (Australia) Nominees Pty Limited 1,058,057 0.85%
Cofactor Llc 1,000,000 0.80%
Swanmark Super Pty Ltd <Rc Swan Super Fund A/C> 1,000,000 0.80%
Ravinna Pty Ltd <Ravinna A/C> 993,992 0.80%
Mr Michael Andrew Whiting and Mrs Tracey Anne Whiting <Whiting Family S/F A/C> 940,000 0.75%
Margaret Frame 923,016 0.74%
Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 1,600 726 251 568 143 3,288

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Blueflag Holdings Pty Ltd 15/12/2021 13,472,500 6.95
Acorn Capital Limited 12/11/2021 10,071,620 6.49
Platinum Investment Management Limited 22/12/2021 34,813,002 17.96

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
20-12-21 Platinum Investment Management Limited 7,795,002 17.45 14.97
15-12-21 Blueflag Holdings Pty Ltd 2,694,500 6.96 6.95
12-11-21 Blueflag Holdings Pty Ltd 2,028,000 7.02 6.96
12-11-21 Acorn Capital Limited 10,071,620 -- 6.49
12-11-21 Platinum Investment Management Limited 9,849,000 16.15 17.45

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $0.215 30 June
2020 $0.125 30 June
2019 $0.097 28 June
ATX Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.